openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Abeona Therapeutics Inc. (NASDAQ: ABEO)

03-19-2020 10:44 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) shares.

An investigation on behalf of current long term investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Abeona Therapeutics Inc..

Investors who are current long term investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in NASDAQ: ABEO stocks follows a lawsuit filed against Abeona Therapeutics Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ABEO stocks, concerns whether certain Abeona Therapeutics directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Abeona's Chemical, Manufacturing and Controls ("CMC") and internal controls and procedures and/or compliance policies were inadequate, that as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient, that consequently, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would reject approval for the start of the VITAL Study until such issues were addressed, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) here

News-ID: 1976531 • Views: 381

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Qurate Retail, Inc. (NASDAQ: …
Qurate Retail, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Qurate Retail, Inc. (NASDAQ: QRTEA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Qurate Retail, Inc. regarding its business, its prospects and its operations were materially false
Lawsuit filed for Investors in shares of Allakos Inc. (NASDAQ: ALLK)
An investor, who purchased shares of Allakos Inc. (NASDAQ: ALLK), filed a lawsuit over alleged Securities Laws violations by Allakos Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Allakos Inc. (NASDAQ: ALLK) have certain options and for certain investors are short and strict deadlines running. Deadline: May 11, 2020. NASDAQ: ALLK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Investors in NASDAQ:LNDC shares over potential Wrong …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors at Landec Corporation. Investors who purchased shares of Landec Corporation (NASDAQ: LNDC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Landec directors breached their fiduciary duties and caused damage to the company and its shareholders. Santa Clara, CA based Landec Corporation, together
Lawsuit filed for Investors in shares of PaySign, Inc. (NASDAQ: PAYS)
An investor, who purchased shares of PaySign, Inc. (NASDAQ: PAYS), filed a lawsuit over alleged Securities Laws violations by PaySign, Inc. Investors in shares of PaySign, Inc. (NASDAQ: PAYS) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 9, 2019, PaySign, Inc lowered its fiscal 2019 revenue guidance to a range of $35 million to $37 million, from prior guidance range of $38 million to $40

All 5 Releases


More Releases for Abeona

Epidermolysis Bullosa (EB) Therapeutics- Pipeline Analysis 2018 | Abeona Therape …
Epidermolysis bullosa (EB), is a rare genetic connective tissue skin disorder that causes blisters and allows skin to become fragile. Blisters and areas of skin loss (erosions) occur in response to minor injury or friction, such as rubbing or scratching. The disease affects 1 out of every 20,000 births in the U.S. Download the sample report @ https://www.pharmaproff.com/request-sample/1130 The symptoms of epidermolysis bullosa are redness and heat around an open area
Fanconi’s Anemia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Resul …
Fanconi anemia is an inherited disease, caused by mutations in FA genes. These genes provide instructions to repair certain types of DNA damage in the human body. The cells of healthy people often repair DNA damage; however, cells affected by Fanconi anemia are not able to repair damages. Download the sample report at: https://www.pharmaproff.com/request-sample/1038 The symptoms associated with the disease are decreased blood cell counts, bone problems, vitiligo, deafness, eye problems,
Batten Disease- Pipeline Including Key Players- Abeona Therapeutics, Amicus Ther …
A new research document is added in HTF MI database of 76 pages, titled as 'Batten Disease - Pipeline Review, H1 2019' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, South America, Asia, Europe & Others and important players/vendors such as Abeona Therapeutics Inc, Amicus Therapeutics Inc, Exicure Inc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Spark Therapeutics Inc The report
Global Fanconi Anemia Drug Market 2018 - Abeona Therapeutics Inc, Genethon SA
Apex Market Reports, recently published a detailed market research study focused on the “Fanconi Anemia Drug Market” across the global, regional and country level. The report provides 360° analysis of “Fanconi Anemia Drug Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Fanconi
Polymer Drug Conjugates Market 2017 -3S Bio, Abeona Therapeutics, Abramson Cance …
Apex Research, recently published a detailed market research study focused on the "Polymer Drug Conjugates Market" across the global, regional and country level. The report provides 360° analysis of "Polymer Drug Conjugates Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Polymer Drug Conjugates industry, and estimates the future trend of
Polymer Drug Conjugates Market Size 2017 3S Bio, Abeona Therapeutics, Allied, As …
Polymer Drug Conjugates Market Research Report A market study ” Global Polymer Drug Conjugates Market ” examines the performance of the Polymer Drug Conjugates market Size 2017. It encloses an in-depth Research of the Polymer Drug Conjugates market state and the competitive landscape globally. This report analyzes the potential of Polymer Drug Conjugates market in the present and the future prospects from various angles in detail. The Global Polymer Drug Conjugates